Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Director | September 12, 2016 | September 14, 2016 |
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 03, 2023 |
| WINDTREE THERAPEUTICS INC /DE/WINT · Entity 8761 | Director | February 03, 2021 | February 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date September 12, 2016 · Filed September 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2026-09-12 | Direct | 12,300 |
Reported balance
After 2016-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-12 · Grant · Acquired 12,300 · Balance 12,300 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
WINDTREE THERAPEUTICS INC /DE/
Report date February 03, 2021 · Filed February 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2031-02-03 | Direct | 30,000 |
Reported balance
After 2021-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-03 · Grant · Acquired 30,000 · Balance 30,000 F1: The stock option shall vest in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in three equal annual installments beginning on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paratek Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-09-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-21 · Disposition to issuer · Disposed 1,069,231 · Balance 258,750 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Row 2 · 2023-09-21 · Disposition to issuer · Disposed 258,750 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger").
F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2023 Filed Sep 21, 2023 13:15 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 258,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019351 · doc4.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4 · price: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. If provided for pursuant to a subscription agreement entered into among the Reporting Person, the Issuer and Resistance TopCo L.P., a Delaware limited partnership ("Topco LP"), the settlement of such Equity Award Consideration may also be made inequity interests of Topco LP. Read SEC document |
| September 21, 2023 Filed Sep 21, 2023 13:15 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Disposition to issuerCommon Stock | 1,069,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019351 · doc4.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,750 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 20:26 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 48,967 | $2.20 | $107,727.40 |
DisclosureSEC source: 0000904454-23-000472 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,327,981 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.19 to $2.21. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:26 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 168,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000472 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376,948 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on March 30, 2021 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:50 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010163 · form4.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 16:44 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 23,489 | $1.99 | $46,743.11 |
DisclosureSEC source: 0000904454-22-000653 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,198 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.94 to $2.01. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:44 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000653 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,687 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on March 15, 2022 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on December 20, 2022. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 20:08 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 61,919 | $1.96 | $121,361.24 |
DisclosureSEC source: 0000904454-22-000627 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179,187 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit awards, pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.93 to $2.01. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 20:08 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 37,831 | $1.98 | $74,905.38 |
DisclosureSEC source: 0000904454-22-000627 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,106 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit awards, pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.96 to $2.00. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 19:58 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 8,805 | $3.47 | $30,553.35 |
DisclosureSEC source: 0000904454-22-000532 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,937 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, as previously reported in a Form 4 filed with the Securities and Exchange Commission (the "SEC") on October 27, 2022, pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.43 to $3.55. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 19:06 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000510 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,742 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on July 31, 2019 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 25, 2022. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 21:06 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 44,519 | $2.66 | $118,420.54 |
DisclosureSEC source: 0000904454-22-000429 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,742 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.58 to $2.78. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:06 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 152,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000429 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302,261 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 19, 2020 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2022. Read SEC document |
| March 15, 2022 Filed Mar 23, 2022 20:41 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 236,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000268 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149,534 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 15/45 of the shares subject to the restricted stock units on December 10, 2022, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001140361-22-009258 · form4.xml · derivative · entry 2 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 21:06 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-009258 · form4.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 20:45 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 49,259 | $4.27 | $210,335.93 |
DisclosureSEC source: 0000904454-21-000840 · edgar.xml · nonDerivative · entry 3 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,284 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.11 to $4.34. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 20:45 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 23,834 | $4.37 | $104,154.58 |
DisclosureSEC source: 0000904454-21-000840 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,543 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.20 to $4.48. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:45 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 13,983 | $4.42 | $61,804.86 |
DisclosureSEC source: 0000904454-21-000840 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,377 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.31 to $4.52. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 19:29 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 33,931 | $5.12 | $173,726.72 |
DisclosureSEC source: 0000904454-21-000630 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,360 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $5.02 to $5.22. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 19:29 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000630 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,291 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on July 31, 2019 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 16, 2021. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 19:25 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 36,654 | $9.70 | $355,543.80 |
DisclosureSEC source: 0000904454-21-000512 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,291 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.58 to $9.97. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| May 27, 2021 Filed Jun 8, 2021 19:25 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 91,636 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000512 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,945 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 19, 2020 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on May 27, 2021. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 18:43 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 303,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000395 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,309 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 15/45 of the shares subject to the restricted stock units on December 10, 2021, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 19:30 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 2,000 | $10.14 | $20,280.00 |
DisclosureSEC source: 0001209191-21-020585 · doc4.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F2 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:30 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001209191-21-020585 · doc4.xml · derivative · entry 3 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-03-11 F4 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 12, 2021 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 19:30 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020585 · doc4.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 12, 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:01 UTC | WINDTREE THERAPEUTICS INC /DE/ WINT · Entity 8761 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-21-002140 · rdgdoc.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The stock option shall vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 19:56 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 26,415 | $6.71 | $177,244.65 |
DisclosureSEC source: 0000904454-20-000822 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,559 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.58 to $6.91. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 19:56 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 18,585 | $6.95 | $129,165.75 |
DisclosureSEC source: 0000904454-20-000822 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,974 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.82 to $7.14. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 18:36 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 20,928 | $5.93 | $124,103.04 |
DisclosureSEC source: 0000904454-20-000761 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,559 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $5.84 to $6.18. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 18:36 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000761 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,487 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on July 31, 2019 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on November 12, 2020. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 16:50 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Exercise / conversionStock Option (right to buy) · Derivative | 39,479 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000904454-20-000693 · edgar.xml · derivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,479 shares Expires 2024-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The Issuer entered into an Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014 (the "Merger Agreement"), by and among the Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and a Delaware corporation then known as Paratek Pharmaceuticals, Inc. ("Old Paratek"). On June 29, 2014, the Reporting Person was granted an option to purchase 1,169,742 shares of the common stock of Old Paratek under Old Paratek's 2014 Equity Incentive Plan at a per share exercise of price of $0.29 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 78,957 shares of the Issuer's common stock at a per share exercise price of $4.30. F3 · derivative.exercise_date: This stock option vested and became exercisable in a series of 48 successive equal monthly installments commencing on January 1, 2015, subject generally to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 16:50 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | Exercise / conversionCommon Stock | 39,479 | $4.30 | $169,759.70 |
DisclosureSEC source: 0000904454-20-000693 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock acquired from the exercise of a stock option. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:27 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 9,595 | $4.75 | $45,576.25 |
DisclosureSEC source: 0000904454-20-000359 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,008 F1 · shares: Sale of shares to cover personal income tax obligations upon settlement of performance-based restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.59 to $4.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:27 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-20-018988 · doc4.xml · derivative · entry 2 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-11 F2 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 12, 2020 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 17:27 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018988 · doc4.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 12, 2020. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:11 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000226 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,603 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2020, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:06 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 14,514 | $3.10 | $44,993.40 |
DisclosureSEC source: 0000904454-19-000741 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,603 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.04 to $3.13. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| October 08, 2019 Filed Oct 8, 2019 20:55 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 7,818 | $3.82 | $29,864.76 |
DisclosureSEC source: 0000904454-19-000678 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,117 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.76 to $3.88. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| October 04, 2019 Filed Oct 8, 2019 20:55 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000678 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,935 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 4, 2019. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 17:13 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 16,265 | $3.98 | $64,734.70 |
DisclosureSEC source: 0000904454-19-000669 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,935 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.81 to $4.21. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 21:50 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001209191-19-021279 · doc4.xml · derivative · entry 1 Loh Evan · CIK 0001622680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 21, 2019 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 18:55 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000282 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,200 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2019, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 16:37 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000149 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,200 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, which were earned on February 1, 2019. These PRSUs will settle in shares of Common Stock on May 8, 2020, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 17:35 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 6,000 | $6.27 | $37,620.00 |
DisclosureSEC source: 0000904454-18-000783 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,700 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.25 to $6.28. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:35 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 5,525 | $6.76 | $37,349.00 |
DisclosureSEC source: 0000904454-18-000783 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,700 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.55 to $7.15. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 19:51 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 5,200 | $8.96 | $46,592.00 |
DisclosureSEC source: 0000904454-18-000663 · edgar.xml · nonDerivative · entry 2 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,225 F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.93 to $9.02. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 19:51 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000663 · edgar.xml · nonDerivative · entry 1 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,425 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 12, 2018. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 20:41 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 8,861 | $9.82 | $87,015.02 |
DisclosureSEC source: 0000904454-18-000642 · edgar.xml · nonDerivative · entry 3 Loh Evan · CIK 0001622680 · Director · President, COO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,425 F3 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.